Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus bortezomib followed by ibrutinib maintenance in relapsed/refractory mantle cell lymphoma
2014-003893-17Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jul 2017
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and bortezomib in mantle cell lymphoma (MCL), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Overall response rate during combination therapy. Started Jul 2017; status: completed.
02
Drugs
ibrutinibbortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2014-003893-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003893-17.